Cancer name Fibrosarcoma
Cancer Type FISA
Immunotherapy type Immunostimulant OR Targeting Therapy
Treatment murine-IL12 plasmids
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Protein
Signature IL-12
Official Symbol IL12A
Mode of action TRAN_D_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental mouse model
Description Total RNA was extracted from tumor masses andcell lyset was prepared to confirm IL-12 and IFN-γ expression byimmunoblotting. The results of real-time PCR indicated that the expression of IL-12 and IFN-γ was significantly (P<U+00BC>0.000) enhanced in the group treated with IL-12 in comparison to the control group. Furthermore, the results of immunoblotting showed that the expression of IL-12and IFN-γ was enhanced in the group treated with GM-CSF incomparison to control group.
PMID 26759095
Title Gene therapy with IL-12 induced enhanced anti-tumor activity in fibrosarcoma mouse model.